Zacks: Analysts Anticipate Heska Corp (HSKA) Will Post Quarterly Sales of $40.59 Million

Share on StockTwits

Equities research analysts expect that Heska Corp (NASDAQ:HSKA) will announce sales of $40.59 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Heska’s earnings, with estimates ranging from $40.26 million to $40.92 million. Heska reported sales of $36.04 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.6%. The firm is expected to report its next quarterly earnings results on Wednesday, February 27th.

On average, analysts expect that Heska will report full year sales of $133.97 million for the current fiscal year, with estimates ranging from $133.64 million to $134.31 million. For the next fiscal year, analysts anticipate that the business will post sales of $148.67 million, with estimates ranging from $146.86 million to $150.48 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Heska.

Heska (NASDAQ:HSKA) last released its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.11. The company had revenue of $30.96 million during the quarter, compared to the consensus estimate of $31.14 million. Heska had a net margin of 1.01% and a return on equity of 11.48%.

Several analysts recently issued reports on HSKA shares. BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a report on Thursday, October 18th. Zacks Investment Research raised shares of Heska from a “hold” rating to a “buy” rating and set a $101.00 price target on the stock in a report on Thursday. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Heska has an average rating of “Hold” and an average target price of $106.20.

Shares of HSKA stock traded down $0.91 on Friday, hitting $90.99. The stock had a trading volume of 1,513 shares, compared to its average volume of 44,750. The company has a market capitalization of $713.24 million, a PE ratio of 43.70 and a beta of 0.88. Heska has a 52-week low of $56.59 and a 52-week high of $114.50.

In other news, CEO Kevin S. Wilson sold 3,190 shares of the firm’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $104.07, for a total transaction of $331,983.30. Following the completion of the transaction, the chief executive officer now owns 106,810 shares in the company, valued at approximately $11,115,716.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director G Irwin Gordon sold 6,700 shares of the firm’s stock in a transaction dated Wednesday, November 21st. The shares were sold at an average price of $98.04, for a total transaction of $656,868.00. Following the transaction, the director now owns 34,268 shares of the company’s stock, valued at approximately $3,359,634.72. The disclosure for this sale can be found here. Insiders have sold 18,702 shares of company stock worth $1,897,809 over the last three months. 15.90% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of HSKA. Vanguard Group Inc lifted its position in shares of Heska by 4.2% in the third quarter. Vanguard Group Inc now owns 405,772 shares of the medical research company’s stock worth $45,978,000 after purchasing an additional 16,376 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Heska by 4.2% in the third quarter. Vanguard Group Inc. now owns 405,772 shares of the medical research company’s stock worth $45,978,000 after purchasing an additional 16,376 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Heska by 8.0% in the third quarter. Legal & General Group Plc now owns 14,373 shares of the medical research company’s stock worth $1,613,000 after purchasing an additional 1,068 shares in the last quarter. Standard Life Aberdeen plc lifted its position in shares of Heska by 6.3% in the third quarter. Standard Life Aberdeen plc now owns 271,338 shares of the medical research company’s stock worth $30,745,000 after purchasing an additional 16,054 shares in the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of Heska by 6.7% in the third quarter. Teachers Advisors LLC now owns 13,674 shares of the medical research company’s stock worth $1,549,000 after purchasing an additional 857 shares in the last quarter. Institutional investors own 89.82% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Further Reading: Quiet Period

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Anticipate Heska Corp  Will Post Quarterly Sales of $40.59 Million
Zacks: Analysts Anticipate Heska Corp Will Post Quarterly Sales of $40.59 Million
Jiyo [OLD]  Achieves Market Cap of $1,332.00
Jiyo [OLD] Achieves Market Cap of $1,332.00
PostCoin Trading Up 22.8% This Week
PostCoin Trading Up 22.8% This Week
The Coca-Cola Co  Expected to Post Quarterly Sales of $7.05 Billion
The Coca-Cola Co Expected to Post Quarterly Sales of $7.05 Billion
Analysts Expect NetScout Systems, Inc.  to Announce $0.41 Earnings Per Share
Analysts Expect NetScout Systems, Inc. to Announce $0.41 Earnings Per Share
$90.00 Million in Sales Expected for NeoPhotonics Corp  This Quarter
$90.00 Million in Sales Expected for NeoPhotonics Corp This Quarter


Leave a Reply

 
© 2006-2019 Zolmax.